Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
Jae Min Lee, Hong Sik Lee, Jong Jin Hyun, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Soon Ho Um, Chang Duck Kim, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, South Korea
Author contributions: Lee HS designed the study; Lee JM and Hyun JJ modified the study methods and performed the study; Choi HS and Kim ES collected the data; Seo YS and Jeen YT analyzed the data; Lee JM wrote the draft; Keum B, Chun HJ, Um SH and Kim CD revised the draft; Lee HS corrected the final draft and approved the manuscript.
Supported by A grant of the Korea Health Technology R and D Project through the Korea Health Industry Development Institute (KHIDI); the Ministry of Health and Welfare, Republic of Korea, No. HI14C3477.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Korea University Anam Hospital.
Informed consent statement: We analyzed the clinical data from each patient who had provided written consent to receive treatment.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hong Sik Lee, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Inchon-ro 73, Seongbuk-gu, Seoul 02841, South Korea. email@example.com
Telephone: +82-2-9205312 Fax: +82-2-9531943
Received: February 3, 2016
Peer-review started: February 9, 2016
First decision: March 31, 2016
Revised: April 8, 2016
Accepted: May 7, 2016
Article in press: May 9, 2016
Published online: July 15, 2016